Morgan Stanley Maintains Overweight on Biogen, Lowers Price Target to $355
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison has maintained an Overweight rating on Biogen (NASDAQ:BIIB) but lowered the price target from $371 to $355.

July 11, 2023 | 12:58 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley has maintained an Overweight rating on Biogen but lowered the price target from $371 to $355.
The news is directly related to Biogen and is important for investors as it involves a change in the price target by a major financial institution. However, the impact on the stock price is uncertain as the rating remains Overweight, indicating a positive outlook, but the price target has been lowered.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100